Compare Amylx Pharmaceuticals Inc (AMLX) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Fiverr International Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Fiverr International Ltd trades at $10.97 (market cap $396.90M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 5× Fiverr International Ltd's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| AMLX | FVRR | |
|---|---|---|
Market Cap | $1.98B | $396.90M |
Sector | Health | Industrials |
52-Week High | $18.70 | $27.25 |
52-Week Low | $7.64 | $9.62 |
Enterprise Value | $1.70B | $127.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Fiverr International (FVRR) trades at $11.04, up 1.1% on the day, with a bullish technical signal and strong valuation metrics including a P/E of 14.34 and P/S of 0.95. Revenue grew to $430.91M in 2025, with net income reaching $20.98M, though Q1 2026 EPS missed expectations. The company maintains a robust gross margin of 81.86% and has beaten earnings estimates in two of the last three quarters, with Q2 2026 results due July 29, 2026.
The outlook is mixed: low valuations and improving profitability support upside, but declining active buyers and a pending legal investigation pose risks. Analyst consensus is cautious with 41% buy ratings. Near-term performance hinges on Q2 earnings demonstrating growth stabilization amid competitive pressures in the gig economy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
